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Methods: Thirty-nine consecutive cases consulted for undetermined 
mediastinal lesions from July 2005 to August 2006 were enrolled. 
Linear echoendoscope and 22-gauge aspiration or 19-gauge Trucut 
needles were used. Final diagnoses were determined by EUS-FNA/CB 
cytology, biospy, surgical pathology, or clinical follow-ups.
Results: Indications for EUS-FNA/CB were for histologic sampling 
in 24 cases (including suspected lung cancer, 9; other malignancy, 6; 
granulomatous disease, 3; unknown lesion, 6) and for stage conﬁrma-
tion of 15 proven malignancies (lung cancer, 11; extra-pulmonary 
malignancy, 4). FNA/CB was performed by mean number of 3.6 passes 
with four minimal complications (fever, 3; pain, 1). Malignant pathol-
ogy was obtained in 12 cases (primary lung cancer, 7; unknown origin, 
4; lymphoma, 1), and nine were deﬁned as benign lesions (tuberculo-
sis, 3; sarcoidosis, 1; reactive lymph node, 4; inconclusive bacterial 
infection, 1). In staging of 16 patients with proven malignancy (nodal 
staging of lung cancer, 11; metastasis of extra-pulmonary malignancy, 
4; recurrence of breast cancer, 1), 14 cases were diagnostic (metastatic, 
7; reactive, 7). Only four specimens (10.3%) were inadequate. Eleven 
of 39 patients (28.2%) had history of tuberculosis (prior pulmonary 
history, 7; present clinical impression, 4). Of the seven, six underwent 
FNA/CB for nodal staging of lung cancer and proved to be diagnostic 
(metastatic, 2; reactive, 4). The diagnostic accuracy of EUS-FNA/CB 
was as follows: overall, 87.2% (34/39); malignancy-related, 92.9% 
(26/28); lung cancer-related, 88.9% (16/18); tuberculosis-related, 
90.9% (10/11). 
Conclusions: EUS-FNA/CB is an accurate diagnostic modality in 
tissue conﬁrmation of undetermined mediastinal lesions. In addition, 
it should be recognized as an indispensable procedure to deﬁne benign 
reactive mediastinal lymph nodes that are commonly encountered in 
highly prevalent area of pulmonary tuberculosis.
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Cancers
Lee, Pyng1 Comans, Emile F.2 Hoekstra, Otto S.2 Sutedja, Tom G.3 
1 Singapore General Hospital, Singapore, 2 Dept of Nuclear Medicine, 
VUMC, Amsterdam, The Netherlands 3 Dept of Pulmonary Diseases, 
VUMC, Amsterdam, The Netherlands 
Introduction: Fluoro-deoxyglucose positron emission tomography 
(PET) has a diagnostic and prognostic value in staging and surveillance 
of non-small cell lung cancer. Several studies have also demonstrated 
its potential in assessing biologic aggressiveness of the primary tumor.
Aims: To evaluate the role of PET for early intraluminal squamous cell 
cancer (ISCC). 
Methods: Patients with early ISCC detected by autoﬂuorescence bron-
choscopy (AF) and conﬁned within the airway wall deﬁned initially by 
high resolution CT at 1 mm (subsequently by multidetector CT at 0.75 
mm slices) underwent PET imaging. 
Results: Sixty current and former smokers (47 males) with median 
age 68 years (range, 62-74) were consecutively entered in this study. 
Twenty four patients had visible tumor margins measuring ≤ 1cm2 
whilst 36 had margins extending beyond the visibility of AFB. PET 
was positive in 23 patients (38%): 7 (7/24, 39%) patients with margin-
visible tumors and 17 (16/36, 44%) with margin-invisible tumors. Nine 
patients underwent surgery for margin-invisible cancers of which 6 
were PET positive. However, 4 of the resected PET positive cancers 
were found to be severe dysplasia in 3 and mild dysplasia in 1. Medi-
astinal staging of the 9 patients who underwent surgery revealed 1 true 
PET positive N1 and 5 true negative N0. Two patients had false PET 
positive lymph nodes which were adjacent to the primary tumors and 1 
had false negative N1 that measured 6mm on CT. No distant metastasis 
was observed. The remaining patients were surgically unﬁt and were 
treated with bronchoscopic therapy. Median follow up was 40 months 
(range, 21-72), 41 patients were alive and 19 deceased. Lung cancer 
related mortality was 13%. PET positive cancers did not result in worse 
survival difference, p= 0.46 (Fig 1). 
Conclusion: Our preliminary results indicated that PET was not useful 
for the evaluation and prognostication of patients with early ISCC con-
ﬁned within the bronchial wall. In fact, false-positive PET results led to 
unnecessary surgery in 4 patients. 
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Background: Non-small cell lung cancer (NSCLC) staging directs 
treatment choice and inﬂuences prognosis. The diagnostic performance 
of conventional FDG-PET scan in lymph node (LN) staging is too 
low to avoid invasive nodal staging. It remains unknown whether the 
diagnostic performance of integrated FDG-PET/CT for LN staging, and 
the calculation of Standard Uptake Values (SUV) could make invasive 
staging redundant.
Methods: We prospectively investigated the mediastinal and/or hilar 
LN in patients with proven NSCLC with an integrated FDG-PET/CT. 
Pathologic conﬁrmation of all suspicious LN was obtained. The diag-
nostic performance of the FDG-PET/CT fusion images and of the SUV 
calculation was measured to the stage the intrathoracic LN.
Results: 105 intrathoracic LN stations from 52 patients with NSCLC 
were characterized. The prevalence of LN malignancy was 36%. The 
sensitivity of integrated FDG-PET/CT to detect malignant LN was 84% 
and its speciﬁcity was 85% (Positive likelihood ratio 5.64, Negative 
likelihood ratio 0.19). SUVMAX, SUVMEAN and the ratio of SUV-
MAX/SUVLIVER values were all signiﬁcantly higher in malignant 
than in benign LN. The ROC area did not differ between these three 
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quantitative variables, but the highest accuracy was found with the 
SUVMAX/SUVLIVER ratio. At a cut-off of 1.5 for the SUVMAX/SU-
VLIVER ratio, the sensitivity and speciﬁcity to detect malignant LN 
invasion was 82% and 93% respectively. 
Conclusion: Integrated FDG-PET/CT has an accuracy which is too 
low to avoid invasive intrathoracic LN staging in patients with NSCLC. 
Moreover, the visual interpretation of the fusion images of the inte-
grated FDG-PET/CT can be conﬁdently replaced by the quantitative 
variable SUVMAX/SUVLIVER, without loss of accuracy for intratho-
racic LN staging. 
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Background and Objectives: Transoesophageal endoscopic ul-
trasound with real time guided ﬁne-needle aspiration (EUS-FNA) 
qualiﬁes as the staging procedure of choice to demonstrate immediate 
irresectability in patients with lung cancer presenting with enlarged 
mediastinal lymph nodes (MLN). This study compared the diagnos-
tic performance of EUS-FNA in lung cancer patients presenting with 
either enlarged or small MLN. 
Design and Patients: A prospective series in unselected lung cancer 
patients referred for EUS-FNA because of suspicion for MLN invasion 
based on the available imaging. Patients were categorized according to 
the transversal diameter of their MLN on CT-scan: group A (all MLN 
<10mm) and group B (at least 1 MLN ≥10mm). A small MLN was 
considered suspicious when either FDG-avid or when lying closely to 
the primary tumor. All patients underwent surgical-pathologic veriﬁca-
tion when EUS-FNA did not demonstrate malignant MLN invasion. 
Diagnostic performance was compared between both groups at the 
patient level (c2-test).
Results: We studied 150 consecutive lung cancer patients (121 men, 
median 65 years), with presumed malignant MLN invasion. In 108 
(72%), there was at least one enlarged MLN, while in 42 (28%), only 
small MLN were found. The sensitivity (with 95% conﬁdence interval) 
to detect malignancy was 98 (92-99)% and 92 (73-99)% for enlarged 
and small MLN, respectively (p=N.S.). The negative predictive value 
of EUS-FNA was 82 (48-97)% and 90 (66-98)% for enlarged and small 
MLN (p=N.S.). EUS-FNA prevented a surgical intervention in 90% 
and 55% of the patients with enlarged or small MLN, respectively. 
Conclusion: Lung cancer patients with suspicious MLN after imaging 
should ﬁrst be staged by EUS-FNA, regardless the size of the MLN. 
However, the moderate negative predictive value of EUS-FNA makes 
surgical-pathologic veriﬁcation still compulsory. 
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Background: Bronchioloalveolar carcinoma (BAC) histologically 
shows a unique replacing growth pattern of tumor cells along the alveo-
lar wall. In 1999, the World Health Organization (WHO) classiﬁcation 
deﬁned BAC as a form of adenocarcinoma with a pure bronchioloal-
veolar growth pattern and no evidence of stromal, vascular, or pleural 
invasion. To date, ground-glass opacity (GGO) on high-resolution com-
puted tomography (HRCT) was well known as one of the characteristic 
ﬁndings of BAC. On the other hand, although BAC is histologically 
subclassiﬁed into mucinous type and non-mucinous type, the differenc-
es in HRCT ﬁndings between two subtypes of BAC have never been 
studied. In this study, we evaluated the differences in HRCT ﬁndings 
between mucinous and non-mucinous BAC.
Methods: Forty-nine patients with BAC less than 3 cm resected be-
tween September 2002 and December 2006 at Shizuoka Cancer Center 
were included. Among 49 BACs, 33 (67%) were subclassiﬁed to non-
mucinous BAC and 16 (33%) were subclassiﬁed to mucinous BAC. 
HRCT ﬁndings in each subtype of BAC were evaluated. 
Results: Table 1 shows HRCT ﬁndings according to subtype of BAC. 
The HRCT ﬁndings included ill-deﬁned margin, consolidation,and 
pseudocavitation were seen more frequently in mucinous BAC com-
pared with non-mucinous BAC (P<0.01). Non-mucinous BAC mainly 
consisted of GGO on HRCT. In contrast, mucinous BAC mainly 
consisted of consolidation on HRCT and the ratio of GGO was less 
than 25% in all cases. Typical HRCT appearance of mucinous BAC is 
shown in Figure 1.
Conclusions: The HRCT ﬁnding of mucinous BAC was clearly dis-
tinguished from non-mucinous BAC. Our present study demonstrated 
that non-mucinous BAC showed heterogeneous HRCT appearance, but 
mucinous BAC showed homogeneous appearance that was ill-deﬁned 
subpleural consolidation with pseudocavitation or air bronchogram sur-
rounded by slight GGO. When these ﬁndings are shown on HRCT, mu-
cinous BAC should be considered as one of the differential diagnoses.
